Clinical Trial

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-06; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2026-06-11
Status change: Not Yet Recruiting → Recruiting 2024-07-18
Trial Details
NCT Number NCT06308159
Lead Sponsor Lantu Biopharma
Conditions Beta-Thalassemia
Enrollment 6 participants
Start Date 2024-05-11
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15